title: Polysaccharide glucomannan isolated from Heterodermia obscurata attenuates acute and chronic pain in mice.
abstract: Glucomannan (GM) is a polysaccharide obtained from Heterodermia obscurata lichens. The present study was conducted to elucidate the antinociceptive effect of GM in behavioural models of acute and chronic pain in mice. GM reduced mechanical allodynia and the levels of interleukin 1-β (IL-1β) in spinal cord and nerve in the partial sciatic nerve ligation (PSNL) model. Systemic treatment with GM inhibited the nociception induced by intraplantar injection of glutamate and by intrathecal injection of N-methyl-d-aspartic acid (NMDA), (±)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), tumour necrosis factor α (TNF-α) and IL-1β. Taken together, our data demonstrate that GM has significant antinociceptive effect in acute and chronic pain, suggesting a potential interest in the development of new clinically relevant drugs for the management of pain.
authors: Laboratório de Neurobiologia da Dor e Inflamação, Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
authors: Marina M
authors: MM
authors: Córdova
authors: Daniel F
authors: DF
authors: Martins
authors: Morgana D
authors: MD
authors: Silva
authors: Cristiane H
authors: CH
authors: Baggio
authors: Elaine R
authors: ER
authors: Carbonero
authors: Andrea C
authors: AC
authors: Ruthes
authors: Marcello
authors: M
authors: Iacomini
authors: Adair R S
authors: AR
authors: Santos
mesh_terms: D059787:Acute Pain / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D000700:Analgesics / Q000302:isolation & purification* / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001203:Ascomycota / Q000737:chemistry*; D001522:Behavior, Animal / Q000187:drug effects; D059350:Chronic Pain / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D018846:Excitatory Amino Acids / Q000008:administration & dosage / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology; D006930:Hyperalgesia / Q000188:drug therapy; D053583:Interleukin-1beta / Q000494:pharmacology; D008026:Ligation / Q000009:adverse effects; D008297:Male; D008351:Mannans / Q000302:isolation & purification* / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D059225:Nociception / Q000187:drug effects; D012584:Sciatic Nerve / Q000187:drug effects / Q000378:metabolism / Q000601:surgery; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000700:Analgesics; D018846:Excitatory Amino Acids; D053583:Interleukin-1beta; D008351:Mannans; D014409:Tumor Necrosis Factor-alpha; C022901:(1-6)-alpha-glucomannan; D018698:Glutamic Acid